New Trial Compares Dara‑Bor‑Dex vs Cy‑Bor‑Dex for Myeloma‑Induced Kidney
EAA241 - Ph 2 RCT Dara-Bor-Dex vs Cy-Bor-Dex in the treatment of Newly Diagnosed Multiple Myeloma with Light Chain Cast Nephropathy (LCCN) [Study activated 8/11/25] @keruakous https://t.co/1NgvVZ3fTA #NCT07085728 #mmsm @eaonc
Phase 3 Trial Tests Daratumumab Regimens For
.@SWOG S2213 Ph3 RCT Dara-VC Induction Followed by ASCT or Dara-VCD Consolidation & Daratumumab Maintenance in Pts w/ Newly Diagnosed AL Amyloidosis [Activated: 12/1/23] https://t.co/OizUfJCc2c #mmsm #bmtsm
Clinicians Favor MRD‑guided Decisions in Myeloma Care
Clinician survey regarding measurable residual disease-guided decision-making in multiple myeloma [Jul 11, 2022] @bdermanmd @ajjakubowiak @mtmdphd @BloodCancerJnl https://t.co/idtv0bQtNB #mmMRD #mmsm #openaccess https://t.co/YyGkqFHeC9
TP53 Classification Uncovers Three Pan‑Cancer Mutation Patterns
TP53-based tripartite classification reveals three distinct mutation patterns across pan-cancer [May 26, 2026] Ma & Dong @CellReports https://t.co/ZDG6Nl2Mxm #PrecisionMedicine https://t.co/Bgye42RPFT
Loss of Y Chromosome Marks Favorable AML Subtype
Loss of the Y chromosome [LOY] defines a biologically distinct subtype of AML, assoc w/ decreased inflammatory response patterns, & favorable outcomes in young male Pts [11/3/25] @mariavelegraki1 et al. @BloodPortfolio https://t.co/3DXkNKTE7s #AMLsm #leusm @OSUHematology
POD24 Signals Urgent Need for Wise Management
POD24 in follicular lymphoma: time to be “wise” [Mar 17, 2022] @JohnPLeonardMD @BloodJournal https://t.co/jLMd14D4Ur #lymsm https://t.co/991dNQe3JH
First‑line Lymphoma Therapies Linked to Higher Osteoporosis Risk
Increased risk of osteoporosis following commonly used first-line treatments for lymphoma: a Danish Nationwide Cohort Study [Feb 11, 2020] Baech et al. Leukemia & Lymphoma https://t.co/oapmDJlQV7 #lymsm #BoneHealth #SuppOnc #geriheme
PET‑CT Can Opportunistically Assess Bone Density in Hodgkin Lymphoma
Opportunistic Evaluation of Bone Mineral Density by PET-CT in Hodgkin Lymphoma Patients [Jun 6, 2019] Cohen et al. Endocr Pract https://t.co/jdxVy80vMB #lymsm #supponc #oncorad #BoneHealth
Zoledronic Acid Prevents Bone Loss in Lymphoma Therapy
Zoledronic Acid for Prevention of Bone Loss in Patients Receiving Primary Therapy for Lymphomas: A Prospective, Randomized Controlled Phase III Trial [Dec 29, 2012] @Lymphoma_Doc @mtmdphd et al. CLML https://t.co/iPOYSXEA1M #lymsm #SuppOnc #BoneHealth #NCT00352846 https://t.co/UlaqHyy65d
B‑cell Cancer Patients Face Higher Severe COVID‑19 Risk
Patients recently treated for B-lymphoid malignancies show increased risk of severe COVID-19: a #CCC19 registry analysis [Mar 9, 2022] @rubinstein_md et al. @mtmdphd @COVID19nCCC @BCD_AACR https://t.co/IMEbvgZafi #COVID19nCancer #COVID19 #bmtsm #leusm #lymsm #mmsm #mpnsm https://t.co/mKoZFJnNBQ
New Trial Compares Dara‑Bor‑Dex vs Cy‑Bor‑Dex in MM with LCCN
EAA241 - Ph 2 RCT Dara-Bor-Dex vs Cy-Bor-Dex in the treatment of Newly Diagnosed Multiple Myeloma with Light Chain Cast Nephropathy (LCCN) [Study activated 8/11/25] @keruakous https://t.co/1NgvVZ3fTA #NCT07085728 #mmsm @eaonc https://t.co/Jrh4teOxUK
Daratumumab Boosts Revlimid Efficacy in Smoldering Myeloma
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUjI5X Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd https://t.co/oQzEYsPoU4
Phase 3 Trial
.@SWOG S2213 Ph3 RCT Dara-VC Induction Followed by ASCT or Dara-VCD Consolidation & Daratumumab Maintenance in Pts w/ Newly Diagnosed AL Amyloidosis [Activated: 12/1/23] https://t.co/OizUfJCc2c #mmsm #bmtsm https://t.co/zWMK1RfCFW
Sevabertinib Shows
EGFR’s Poor Sibling {Editorial} [April 15, 2026] @DCarboneMD @NEJM https://t.co/DjV4gAtKMk #lcsm #PrecisionMedicine RE: #NCT05099172 Sevabertinib in Advanced HER2-Mutant Non–Small-Cell Lung Cancer https://t.co/63kCdZ6JOJ
Integrated Academic-Community Tumor Board Enhances Precision Medicine
Implementation & Utility of an Integrated Academic-Community #PrecisionMedicine Molecular Tumor Board [MTB] [Jul 5, 2017] @meburkard et al. @JCOPO_ASCO https://t.co/HOWIx826Lm https://t.co/1JmBdW6K5c
Distinguishing Reportable vs Pragmatic Actionability in Precision Medicine
Reportable actionability versus pragmatic actionability: implementing #PrecisionMedicine at three large health systems. @mtmdphd et al. Abstract 6539 #ASCO18 https://t.co/bT29xyztZd https://t.co/tjxR7LC1hH
Molecular Tumor Boards Cut Costs, Reduce Recommendation Discordance
Quantifying the Value of Molecular Tumor Board: Discordance Recommendation Rate & Drug Cost Avoidance [10/20/22] Walters @JimW9200 @antonyruggeri @mullane_michael Hunt, Wilson, Ramczyk, @mtmdphd @JCOPO_ASCO https://t.co/OORXChBGjx #PrecisionMedicine #hpeonc @Aurora_Cancer https://t.co/ZUQXq4npfh
First-Year Lessons Coordinating an Oncology Precision Medicine Clinic
Coordinating an Oncology #PrecisionMedicine Clinic w/in an Integrated Health System: Lessons Learned in Year 1 [1/28/19] @mtmdphd Godden, Wham @antonyruggeri @mullane_michael Wilson @shamsvirani Weissman, Ramczyk, Vanderwall @JimW9200 @Aurora_Cancer @JPCRR https://t.co/bxgjOfLhwk https://t.co/4pR7nFLzGW
Overcoming Barriers to Community Oncology Precision Medicine
Implementing #PrecisionMedicine Programs and #ClinicalTrials in the Community-Based Oncology: Practice: Barriers and Best Practices - @JLErsek @lorablk @mtmdphd & @EdKimMDLCI #ASCO18 Education Book https://t.co/ahsmfePatk #NCORP
PurIST Classifier Validated for Tailored Pancreatic Cancer Therapy
Real-World Validation of the Purity Independent Subtyping of Tumors Classifier for Informing Therapy Selection [PurIST @TempusAI] in Pancreatic Ductal Adenocarcinoma [Sep 4, 2025] @stephwen et al. @JCOPO_ASCO https://t.co/R24DErvaB4 #pancsm #PrecisionMedicine https://t.co/KNJHtWovqT
Biliary Cancer Subtypes Show Distinct Immune Signatures
Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures [Jun 8, 2022] @kabir_mody et al. @MarkYarchoan @JCOPO_ASCO https://t.co/IN6UsL5jvN #hpbcsm #PrecisionMedicine https://t.co/p3BzJ82oxA
BRAF Class II/III Mutations Represent Unmet Clinical Need
Real-world clinical genomic analysis of Pts w/ BRAF mutated cancers identifies BRAF class II & III as a population of unmet medical need [3/7/22] Severson etal #ESMO2240P @TempusAI https://t.co/s5PEBEczlv @Annals_Oncology DOI: https://t.co/c3wxWyUuX0 #PrecisionMedicine #caxtx
ASCO Endorses Somatic Genomic Testing for Advanced Cancers
Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: @ASCO Provisional Clinical Opinion [Feb 17, 2022] @CDebyaniPhD et al. @JCO_ASCO https://t.co/hfHUBS3Unx #PrecisionMedicine https://t.co/GwYOMRD1hh
BRAFV600E‑mutated Pediatric Gliofibroma Shows Fleeting Therapy Response
Rare Pediatric Invasive Gliofibroma Has BRAFV600E Mutation and Transiently Responds to Targeted Therapy Before Progressive Clonal Evolution [Mar 27, 2019] @KanevaMD et al. @JCOPO_ASCO https://t.co/oNbfrK7EZr #PrecisionMedicine #btsm https://t.co/V7k9vEiqKm
KRASG12C Mutations Linked to Distinct Immuno‑oncology Biomarkers
Landscape of KRASG12C, Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in KRAS-Mutated Cancers [Mar 23, 2022] @SalemGIOncDoc et al. @JCOPO_ASCO https://t.co/iehC82lyA4 #ImmunoOnc #PrecisionMedicine @TempusAI https://t.co/wZzfdnBoXU
Real‑World Data Uncovers Unique Profile of Metastatic ILC
Molecular Characterization of Patients with Metastatic Invasive Lobular Carcinoma: Using Real-World Data to Describe This Unique Clinical Entity [Sep 10, 2025] Davis et al. @CCR_AACR https://t.co/eY0etUfQhQ #bcsm #PrecisionMedicine #camoldx @TempusAI https://t.co/WBcB4uGito
Comprehensive Genomic Panel Broadens Community Oncology Treatment Options
Unique Features of a Comprehensive Genomic Profiling Panel: Expanding Treatment Options in a Value-Based Community Oncology Network [Mar 9, 2026] La Porte et al. @DrEzraCohen @JCOPO_ASCO https://t.co/tDi3kbxdvX #PrecisionMedicine #hemeonc @TempusAI https://t.co/6QKo7c3oH2
Chromosomal Abnormalities Impact Myeloma Survival Differently Across Populations
Population differences in the associations between chromosomal abnormalities and overall survival of multiple myeloma [Jan 31, 2025] Bei Wang et al. @Bloodneoplasia https://t.co/IFPgCwpGo6 #mmsm #PrecisionMedicine #cancerdisparities https://t.co/vpNoEupRPG
High CTC Levels Signal Aggressive, Genomically Complex Myeloma
Elevated circulating tumor cells [#cactc] reflect high proliferation and genomic complexity in multiple myeloma [Sep 23, 2025] Garces et al. @Hemasphere_EHA https://t.co/R8ehW89gTn #mmsm #cagenome https://t.co/Ms6SGwbxcL
Mapping Genomic Landscape of Multiple Myeloma Precursors
Genomic landscape of multiple myeloma and its precursor conditions [May 21, 2025] Jean-Baptiste Alberge et al. @IrenemGhobrial @NatureGenet https://t.co/DDWGRrpI4Y #mmsm #PrecisionMedicine #cagenome https://t.co/X0OPLHNkdG
Multiple Myeloma Evades GPRC5D T‑Cell Engagers via Multim
Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myeloma [Jan 15, 2026] @hollyleeYJ et al. @NBahlis @NatureMedicine https://t.co/mz393mPMAq #mmsm #PrecisionMedicine #tcellrx THREAD: https://t.co/lNX9b7LsnR HT @AuclairDan https://t.co/d0JNE6pb5x
Approach to Unexplained Cytopenia in Clinical Practice
How I manage patients with unexplained cytopenia [Apr 10, 2025] Malcovati & Cazzola @BloodPortfolio https://t.co/bfCmp1AJ4R #camoldx #PrecisionMedicine https://t.co/LpQhp9W79v
New Trial Compares Dara‑Bor‑Dex vs Cy‑Bor
EAA241 - Ph 2 RCT Dara-Bor-Dex vs Cy-Bor-Dex in the treatment of Newly Diagnosed Multiple Myeloma with Light Chain Cast Nephropathy (LCCN) [Study activated 8/11/25] @keruakous https://t.co/1NgvVZ3fTA #NCT07085728 #mmsm @eaonc https://t.co/n2tSuJXS5b
Daratumumab Boosts Revlimid Efficacy in Smoldering Myeloma
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUjI5X Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd https://t.co/VPIH8iphVP
Phase 3 Trial Tests Daratumumab Reg
.@SWOG S2213 Ph3 RCT Dara-VC Induction Followed by ASCT or Dara-VCD Consolidation & Daratumumab Maintenance in Pts w/ Newly Diagnosed AL Amyloidosis [Activated: 12/1/23] https://t.co/OizUfJCc2c #mmsm #bmtsm https://t.co/xv1RlCv8gl
Durvalumab Plus FLOT Improves Resectable Gastric Cancer Outcomes
EFS in MATTERHORN: A Ph3 RCT of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin & docetaxel chemotherapy (FLOT) in resectable gastric/gastroesophageal junction cancer (GC/GEJC) - @YJanjigianMD et al. #ASCO25 LBA5 https://t.co/lW8KUtXdB3 #NCT04592913 #stcsm #esocsm
CtDNA‑guided Cam
Camizestrant + CDK4/6i for the Tx of emergent ESR1 mutations during 1L endocrine-based therapy & ahead of disease progression in Pts w/ HR+/HER2– advanced breast cancer (ABC): ...ctDNA-guided SERENA-6 trial - Turner et al. #ASCO25 LBA4 https://t.co/9jFfuGd1IS #NCT04964934 #bcsm
Rusfertide Shows Efficacy in Phase 3 PV Trial
Results from VERIFY, a phase 3, double-blind, placebo (PBO)-controlled study of rusfertide for treatment of polycythemia vera (PV) - @KuykendallMd et al. #ASCO25 LBA3 https://t.co/XID3tkj6Sk #NCT05210790 #mpnsm
Adjuvant Nivolumab Boosts Outcomes in High‑Risk HNSCC
NIVOPOSTOP (GORTEC 2018-01): Ph3 RCT of adjuvant nivolumab added to radio-chemotherapy in Pts w/ resected head & neck squamous cell carcinoma at high risk of relapse - Bourhis et al. #ASCO25 LBA2 https://t.co/Uxh4JhZyDE #NCT03576417 #hncsm #ImmunoOnc
Atezolizumab Boosts Adjuvant Therapy for dMMR Colon
RCT of standard chemotherapy +/- atezolizumab as adjuvant therapy for Pts w/ stage III deficient DNA mismatch repair (dMMR) colon cancer (@ALLIANCE_org A021502; ATOMIC) - @FASinicropeMD et al. #ASCO25 LBA1 https://t.co/cGalNPlxMe #NCT02912559 #crcsm
WGS Uncovers KMT2A PTD, Surpassing Old AML Tests
Detection of KMT2A partial tandem duplication (PTD) in AML by whole genome sequencing (WGS): Addressing limitations of traditional techniques in the era of revumenib approval - Huether et al. #ASCO25 Abst 6532 https://t.co/EEsXm7JGdv #AMLsm #leusm #PrecisionMedicine @TempusAI
First Tumor NGS Usage Varies Across Top Five Cancers
Utilization and timing of first tumor next-generation sequencing testing (NGS) in Pts w/ 5 most common cancers in the USA - @chadihcmd et al. @huntsmancancer #ASCO25 Abstract 11014 https://t.co/lWefncnTb2 #PrecisionMedicine #hemonc #bcsm #crcsm #lcsm #pancsm #pcsm https://t.co/oIX8QTRD8x
Daraxonrasib Beats Chemo in Pre‑treated Metastatic Pancreatic Cancer
#ASCO26 LBA5 - Wolpin - Daraxonrasib RAS(ON) multi-selective inhibitor vs chemo in prior Tx metastatic pancreatic adenocarcinoma (mPDAC) - Ph3 RASolute 302 [May 31, 2026] https://t.co/oWEeVo2oyq #NCT06625320 #pancsm #caxtx #PrecisionMedicine https://t.co/adz922fg5z
Ivonescimab Plus Chemo Rivals Tislelizumab in First‑line sqNSCLC
#ASCO26 LBA4 - Zhiwei - Ivonescimab + chemo vs tislelizumab + chemo 1L sq NSCLC - Ph3 HARMONi-6 [May 31, 2026] Zhiwei et al. https://t.co/oWEeVo2oyq #NCT05840016 #lcsm #ImmunoOnc https://t.co/NP2qr2gPuY
Adjuvant Selpercatinib Shows Promise
#ASCO26 LBA3 - Goldman - EFS w/ adjuvant sepercatinib in stage IB-IIIA RET fusion-positive NSCLC: Ph3 LIRETTO-432 trial https://t.co/oWEeVo2oyq #NCT04819100 #lcsm #PrecisionMedicine https://t.co/HWIS9mg57w
Phase 3 Trial Shows Abemaciclib Benefits Advanced Liposarcoma
#ASCO26 LBA2 - Dickson -SARC041: Ph3 DBRCT abemaciclib vs placebo in Pts w/ adv dedifferentiated liposarcoma [May 31, 2026] https://t.co/oWEeVo2oyq #NCT04967521 #scmsm https://t.co/uD6A9JmBCn
New Model Enables Multi‑Institutional Sarcoma Video Collaboration
A model for multi-institutional, multidisciplinary sarcoma videoconferencing [2013] Attia, Maki, @JTrentMDPhD , Okuno, Indelicato, @nickwebbermd , Curtis, Kozak #ASCO13 Abstr 10521 https://t.co/opAHZRDTTr #scmsm
Genomic Profiling Boosts Survival for Advanced Sarcoma Patients
Using Tumor Genomic Profiling to Guide Treatment Selection Extends Survival in Advanced Sarcoma [May 10, 2019] @ASCO Daily News #scmsm #PrecisionMedicine https://t.co/8625ixTvQu
Pharma Leaders Leverage Twitter For
A healthcare case study of @ASCO, @Novartis & @Boehringer conversation on twitter [Jan 22, 2015] via @whydotpharma (now @SiljaChouquet ) https://t.co/6xeCaqs8GO #socpharm
Perioperative
#ASCO26 LBA1 - Taplin - Perioperative APA + ADT - prostate CA [May 31, 2026] https://t.co/oWEeVo2oyq #NCT03767244 #pcsm https://t.co/8o91ntAwL9